Arcutis Biotherapeutics (ARQT) insider Matsuda plans sale after stock vesting

Rhea-AI Filing Summary

Masaru Matsuda filed a notice of proposed sale of 1,230 shares of Arcutis Biotherapeutics common stock. The shares are to be sold through Merrill Lynch on the NASDAQ, with an anticipated sale date of August 3, 2026, and originated from Restricted Stock Vesting on August 1, 2026. Over the prior three months, Matsuda sold 8,256 shares of common stock on May 4, 2026, for proceeds of $192,415.53.

Key Figures

Planned shares to be sold: 1,230 shares Planned sale date: 08/03/2026 Shares from restricted stock vesting: 1,230 shares +2 more

5 metrics

Planned shares to be sold 1,230 shares Common stock sale planned through Merrill Lynch on August 3, 2026

Planned sale date 08/03/2026 Anticipated date of sale of 1,230 common shares on NASDAQ

Shares from restricted stock vesting 1,230 shares Originating from Restricted Stock Vesting on August 1, 2026

Shares sold in past 3 months 8,256 shares Common stock sale reported for May 4, 2026

Proceeds from prior sale $192,415.53 Total consideration for 8,256 shares sold on May 4, 2026

Key Terms

Form 144, Restricted Stock Vesting, Securities To Be Sold

3 terms

Form 144 regulatory

"What does Arcutis Biotherapeutics (ARQT) disclose in this Form 144?"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"The 1,230 shares are reported as arising from Restricted Stock Vesting on August 1, 2026"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Securities To Be Sold regulatory

"144: Securities To Be Sold Common | 08/01/2026 | Restricted Stock Vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 05:08 PM Accepted by SEC EDGAR 08/03/2026 - 05:07 PM Learn about SEC filing dates

FAQ

What does Arcutis Biotherapeutics (ARQT) disclose in this Form 144?

The filing discloses that Masaru Matsuda intends to sell 1,230 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on August 3, 2026, following restricted stock vesting.

How many ARQT shares is Masaru Matsuda planning to sell?

Masaru Matsuda plans to sell 1,230 shares of Arcutis Biotherapeutics common stock. The planned transaction is to occur through Merrill Lynch on the NASDAQ with an anticipated sale date of August 3, 2026.

What is the origin of the ARQT shares being sold by Masaru Matsuda?

The 1,230 shares of Arcutis Biotherapeutics common stock are reported as arising from Restricted Stock Vesting on August 1, 2026. This indicates they came from an equity award that recently vested before the planned sale.

What ARQT stock sales occurred in the past three months for this filer?

The filer reports a prior sale of 8,256 shares of Arcutis Biotherapeutics common stock on May 4, 2026, generating proceeds of $192,415.53 during the preceding three-month period.

Who is the reporting person in this Arcutis Biotherapeutics (ARQT) Form 144?

The reporting person is Masaru Matsuda, with a listed address at 3027 Townsgate Rd, Suite 300, Westlake Village, CA 91361, who is providing advance notice of planned sales of Arcutis Biotherapeutics common stock.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	1230	32123.66	125083374	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			1230	08/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	05/04/2026	8256	192415.53

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)